Sensus Healthcare (SRTS) Projected to Post Earnings on Thursday

Sensus Healthcare (NASDAQ:SRTS) will likely be releasing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect the company to announce earnings of ($0.0550) per share and revenue of $6.61 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.41). The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million. Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.

Sensus Healthcare Trading Up 3.8%

Sensus Healthcare stock opened at $3.30 on Wednesday. Sensus Healthcare has a 52 week low of $2.66 and a 52 week high of $5.49. The stock has a 50 day moving average of $2.99 and a 200-day moving average of $3.48.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SRTS. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. Finally, Lake Street Capital dropped their target price on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $5.83.

Insider Buying and Selling

In other Sensus Healthcare news, Director Eric Sachetta bought 37,537 shares of the stock in a transaction on Friday, August 28th. The stock was purchased at an average price of $3.44 per share, for a total transaction of $129,127.28. Following the completion of the purchase, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This trade represents a 16.32% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired a total of 120,171 shares of company stock valued at $405,230 over the last three months. Insiders own 10.20% of the company’s stock.

About Sensus Healthcare

Sensus Healthcare, Inc. is a medical device company focused on non-invasive treatment technologies for dermatologic and oncologic conditions. The company develops and commercializes superficial radiotherapy systems designed to deliver low-energy X-rays to targeted areas of the skin. Its principal products include the SRT-100 and SRT-100 Vision systems, which are used by physicians to treat non-melanoma skin cancers, including basal cell and squamous cell carcinomas, as well as keloids. The systems are intended to provide an alternative to certain surgical procedures and are used in dermatology, radiation oncology and other clinical settings.